Startups
The WHO estimate that c 50% of all vaccines manufactured are wasted in spite of c $400m p.a. spent on the global Cold Chain. Stablepharma aims to ensure that all vaccines can be removed from the refrigerated cold chain and stored for months or even years at room temperature.
The Problem: Vaccines are perishable requiring constant, precise refrigeration from the manufacturer to the patient, be it in a hospital or a remote clinic in Africa.
The Solution: StablevaX is a patented invention which enables vaccines to be transported & stored for many years without refrigeration whilst complying with current protocols set by the WHO. It’s an important breakthrough that can save many lives.
Stablepharma has partnered with a WHO pre-qualified European vaccine manufacturer as well as world-class UK academic institutions, in order to advance our work on the thermo-stabilisation of T&D containing vaccines and mRNA vaccine technologies. Stablepharma was delighted to received an Innovate UK grant to progress our work in these areas.
The StablevaX products comprise of approved vaccines and are intended to be pre-dosed.
Join us in changing the future of healthcare!
The Problem: Vaccines are perishable requiring constant, precise refrigeration from the manufacturer to the patient, be it in a hospital or a remote clinic in Africa.
The Solution: StablevaX is a patented invention which enables vaccines to be transported & stored for many years without refrigeration whilst complying with current protocols set by the WHO. It’s an important breakthrough that can save many lives.
Stablepharma has partnered with a WHO pre-qualified European vaccine manufacturer as well as world-class UK academic institutions, in order to advance our work on the thermo-stabilisation of T&D containing vaccines and mRNA vaccine technologies. Stablepharma was delighted to received an Innovate UK grant to progress our work in these areas.
The StablevaX products comprise of approved vaccines and are intended to be pre-dosed.
Join us in changing the future of healthcare!
Overview
Location
United Kingdom, England, Bath
Employees
11-50
Total raised
$2.6M
Founded date
2012
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 7, 2026 | Stablepharma Doses First Patient in Pivotal Phase 2b Trial After Positive Clinical Results | Ozgur Tuncer, CEO & Exectutive Director Dr Karen O'Hanlon, Chief Operating Officer Stablepharma's Fridge-free Tetanus Diphtheria Vaccine - SPVX02 The pivotal 160-patient study represents the final clinical step towards commercialisation... |
| Sep 9, 2026 | 6 Startups Crowdfunding w/c 07.09.2026 | This article does not constitute financial advice and is designed for information purposes only. It’s a new week and there’s a new group of startups pitching their case to the crowd. This week’s roundup is a strong showcase of deep tech sol... |
| Aug 5, 2026 | The Lancet’s eClinicalMedicine Publishes Phase I Data for SPVX02, a Fridge-free Td Vaccine Stable for 24 Months at 30°C | Stablepharma's Fridge-free Tetanus Diphtheria Vaccine - SPVX02 Özgür Tuncer CEO & Executive Director Dr Karen O'Hanlon, Chief Operating Officer Stablepharma announce Phase 1 clinical trial results for SPVX02, a thermostable reformulatio... |
| Jun 15, 2026 | Stablepharma and AFT Move to Expand Fridge-Free Vaccine Distribution Following Positive Clinical Data | Stablepharma, specialists in thermostable formulations, signed LOI with AFT for distribution of SPVX02, a fridge-free Td vaccine, in UK, Canada, Australia & NZ With AFT Pharmaceuticals, we are working to translate our fridge-free innova... |
| Feb 20, 2025 | Bridging the Skills Gap: The Future of Shipbuilding in the Age of AI | The shipbuilding industry stands at a crossroads. As technology advances, the demand for skilled workers is shifting. A recent report from the National Manufacturing Institute Scotland (NMIS) highlights this urgent need. The report emphasiz... |
| Feb 20, 2025 | Stablepharma Receives €2.5M EIC Accelerator Grant | Stablepharma, a London, UK-based biotechnology firm, received a €2.5M grant through the EIC Accelerator Program. Led by Ozgur Tuncer, CEO & Executive Director, and Dr. Steve Chatfield, Non-Executive Chairman, Stablepharma has developed ... |
| Startup Funding Club takes part in the Asian Productivity Organisation’s Study Mission | Startup Funding Club was invited to present its company and four of its funded Internet-of-Things startups to delegates from the Asian Productivity Organisation In the early-stage investment world, the weeks leading up to April 6th are the... | |
| A new way of categorising businesses | The world changes all the time, and so do businesses. Some time ago, when talking about companies to fund, we would typically refer to the sector in which they operated – e.g. Retail or Property –, their business model – B2B or B2C –, or th... |
Reviews 0
FAQ about Stablepharma Limited
When was Stablepharma Limited founded?
Stablepharma Limited was founded in 2012.
How much funding has Stablepharma Limited raised?
Stablepharma Limited has raised $2.6M in total across 1 funding round.
What has the press written about Stablepharma Limited?
Parsers VC has collected 9 articles mentioning Stablepharma Limited, among them “Stablepharma Doses First Patient in Pivotal Phase 2b Trial After Positive Clinical Results” (Oct 7, 2026) and “6 Startups Crowdfunding w/c 07.09.2026” (Sep 9, 2026).
Is Stablepharma Limited still active?
Yes, Stablepharma Limited is active; its latest activity on Parsers VC dates from Oct 15, 2026.